These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37113064)

  • 1. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
    Jang A; Lanka SM; Huang M; Casado CV; Caputo SA; Sweeney PL; Gupta K; Pocha O; Habibian N; Hawkins ME; Lieberman AD; Schwartz J; Jaeger EB; Miller PJ; Layton JL; Barata PC; Lewis BE; Ledet EM; Sartor O
    Prostate; 2023 Aug; 83(11):1028-1034. PubMed ID: 37113064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
    Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
    JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
    Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.
    Nørgaard M; Bjerre MT; Fredsøe J; Vang S; Jensen JB; De Laere B; Grönberg H; Borre M; Lindberg J; Sørensen KD
    Clin Chem; 2023 Apr; 69(4):386-398. PubMed ID: 36762756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
    George DJ; Halabi S; Heath EI; Sartor AO; Sonpavde GP; Das D; Bitting RL; Berry W; Healy P; Anand M; Winters C; Riggan C; Kephart J; Wilder R; Shobe K; Rasmussen J; Milowsky MI; Fleming MT; Bearden J; Goodman M; Zhang T; Harrison MR; McNamara M; Zhang D; LaCroix BL; Kittles RA; Patierno BM; Sibley AB; Patierno SR; Owzar K; Hyslop T; Freedman JA; Armstrong AJ
    Cancer; 2021 Aug; 127(16):2954-2965. PubMed ID: 33951180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
    Caputo SA; Hawkins M; Jaeger EB; Fleming W; Casado C; Manogue C; Huang M; Lieberman A; Light M; Sussman IP; Miller P; Barata PC; Lewis BE; Layton JL; Ledet EM; Antonarakis ES; Sartor O
    Prostate; 2023 Jun; 83(9):879-885. PubMed ID: 36959766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer.
    Deol ES; Sanfilippo KM; Luo S; Fiala MA; Wildes T; Mian H; Schoen MW
    J Geriatr Oncol; 2023 Jun; 14(5):101520. PubMed ID: 37263065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
    George DJ; Ramaswamy K; Huang A; Russell D; Mardekian J; Schultz NM; Janjan N; Freedland SJ
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):524-530. PubMed ID: 34732856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
    Armstrong AJ; Al-Adhami M; Lin P; Parli T; Sugg J; Steinberg J; Tombal B; Sternberg CN; de Bono J; Scher HI; Beer TM
    JAMA Oncol; 2020 Feb; 6(2):217-225. PubMed ID: 31830211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
    Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
    Tucker MD; Zhu J; Marin D; Gupta RT; Gupta S; Berry WR; Ramalingam S; Zhang T; Harrison M; Wu Y; Healy P; Lisi S; George DJ; Armstrong AJ
    Cancer Med; 2019 Aug; 8(10):4644-4655. PubMed ID: 31270961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
    Ramalingam S; Humeniuk MS; Hu R; Rasmussen J; Healy P; Wu Y; Harrison MR; Armstrong AJ; George DJ; Zhang T
    Urol Oncol; 2017 Jun; 35(6):418-424. PubMed ID: 28126272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
    Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
    Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Nadal R; Zhang Z; Rahman H; Schweizer MT; Denmeade SR; Paller CJ; Carducci MA; Eisenberger MA; Antonarakis ES
    Prostate; 2014 Nov; 74(15):1560-8. PubMed ID: 25176007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.